A Case of Rapid Progressive Neurosyphilis in Patient with Ankylosing Spondylitis Who Is Treating Anti-interleukin 17A Monoclonal Antibody, Secukinumab
Journal of Rheumatic Diseases
; : 278-281, 2019.
Article
en En
| WPRIM
| ID: wpr-766189
Biblioteca responsable:
WPRO
ABSTRACT
Anti-interleukin 17A agent, secukinumab is remarkably effective for treating patients with ankylosing spondylitis. However, the main safety concern of secukinumab is an increased risk of infection. Generally, neurosyphilis occurs a few years after the primary syphilitic infection. Rare cases of progressing to neurosyphilis with a much lower latency were reported. We report a case of rapid progressive neurosyphilis involving hearing loss in both ears in a patient with ankylosing spondylitis who was treated with secukinumab.
Palabras clave
Texto completo:
1
Base de datos:
WPRIM
Asunto principal:
Espondilitis Anquilosante
/
Interleucina-17
/
Oído
/
Pérdida Auditiva
/
Neurosífilis
Límite:
Humans
Idioma:
En
Revista:
Journal of Rheumatic Diseases
Año:
2019
Tipo del documento:
Article